Adrian Curran1, Jhon Rojas2, Alfonso Cabello3, Jesús Troya4, Arkaitz Imaz5, Pere Domingo6, Esteban Martinez2, Pablo Ryan4, Miguel Górgolas3, Daniel Podzamczer5, Hernando Knobel7, Félix Gutiérrez8, Esteban Ribera9. 1. Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain acurran@vhebron.net. 2. Hospital Clinic-IDIBAPS, Universitat de Barcelona, Barcelona, Spain. 3. Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain. 4. Hospital Universitario Infanta Leonor, Madrid, Spain. 5. Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet, Spain. 6. Hospital Arnau de Vilanova, Lleida, Spain. 7. Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain. 8. Hospital General de Elche, Universidad Miguel Hernández, Alicante, Spain. 9. Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Abstract
OBJECTIVES: To describe the effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen in naive HIV-1-infected patients, as there is a lack of data with this combination. METHODS: This was an observational, retrospective, multicentre study in eight Spanish hospitals. All antiretroviral-naive patients ≥18 years old and starting abacavir/lamivudine + rilpivirine were included. Effectiveness (ITT and on-treatment) and safety (adverse events and laboratory parameters) were assessed during follow-up. Values are expressed as n (%) or median (IQR). The Wilcoxon signed-rank test was used to compare baseline and 6 and 12 month values. RESULTS: Eighty-four patients were included [93% males, age = 36 (30-45) years]. Time since HIV diagnosis was 12 (4-35) months. Fifty-one per cent of patients had comorbidities. Baseline CD4+ was 425 (340-519) cells/mm3 and baseline HIV-RNA was 19 000 (9500-42 000) copies/mL. Median follow-up was 18 (9-22) months; 100% and 68% patients with at least 6 and 12 months, respectively. At 6 and 12 months effectiveness was 94% and 86% by ITT analysis and 96% and 97% by on-treatment analysis. At 12 months, there were significant increases in CD4+ (+262 cell/mm3) and HDL cholesterol (+4 mg/dL) and a significant decrease in the total cholesterol/HDL cholesterol ratio (-0.2). There were two (2.4%) virological failures (HIV-RNA 50-100 copies/mL); one patient later achieving virological suppression without changing the treatment. Six patients (7.1%) changed treatment due to reasons other than virological failure or side effects. One patient discontinued treatment due to gastrointestinal complaints attributed to abacavir/lamivudine. CONCLUSIONS: Abacavir/lamivudine + rilpivirine was an effective and safe option in a selected group of HIV-1-infected treatment-naive patients.
OBJECTIVES: To describe the effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen in naive HIV-1-infectedpatients, as there is a lack of data with this combination. METHODS: This was an observational, retrospective, multicentre study in eight Spanish hospitals. All antiretroviral-naive patients ≥18 years old and starting abacavir/lamivudine + rilpivirine were included. Effectiveness (ITT and on-treatment) and safety (adverse events and laboratory parameters) were assessed during follow-up. Values are expressed as n (%) or median (IQR). The Wilcoxon signed-rank test was used to compare baseline and 6 and 12 month values. RESULTS: Eighty-four patients were included [93% males, age = 36 (30-45) years]. Time since HIV diagnosis was 12 (4-35) months. Fifty-one per cent of patients had comorbidities. Baseline CD4+ was 425 (340-519) cells/mm3 and baseline HIV-RNA was 19 000 (9500-42 000) copies/mL. Median follow-up was 18 (9-22) months; 100% and 68% patients with at least 6 and 12 months, respectively. At 6 and 12 months effectiveness was 94% and 86% by ITT analysis and 96% and 97% by on-treatment analysis. At 12 months, there were significant increases in CD4+ (+262 cell/mm3) and HDL cholesterol (+4 mg/dL) and a significant decrease in the total cholesterol/HDL cholesterol ratio (-0.2). There were two (2.4%) virological failures (HIV-RNA 50-100 copies/mL); one patient later achieving virological suppression without changing the treatment. Six patients (7.1%) changed treatment due to reasons other than virological failure or side effects. One patient discontinued treatment due to gastrointestinal complaints attributed to abacavir/lamivudine. CONCLUSIONS:Abacavir/lamivudine + rilpivirine was an effective and safe option in a selected group of HIV-1-infected treatment-naive patients.
Authors: Z C Lim; G S Hoo; J H Ang; C B Teng; L W Ang; C C Lee; Y S Leo; H L Law; O T Ng; C S Wong Journal: AIDS Res Ther Date: 2021-11-01 Impact factor: 2.250
Authors: Nadia Galizzi; Laura Galli; Andrea Poli; Nicola Gianotti; Elisabetta Carini; Alba Bigoloni; Giuseppe Tambussi; Silvia Nozza; Adriano Lazzarin; Antonella Castagna; Daniela Mancusi; Roberta Termini Journal: PLoS One Date: 2018-02-16 Impact factor: 3.240